Tien Liang BioTech Co (ROCO:4127) ROCE %: 1.63% (As of Dec. 2025)

What is Tien Liang BioTech Co ROCE %?

Tien Liang BioTech Co ROCO:4127 -0.29% 38 ROCE % is 1.63% as of Dec. 2025. GuruFocus rates ROCO:4127 with a GF Score™ of 38/100 and a GF Value™ of NT$39.20 (Significantly Overvalued). The stock has 8 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tien Liang BioTech Co's annualized ROCE % for the quarter that ended in Dec. 2025 was 1.63%.

Tien Liang BioTech Co (ROCO:4127) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tien Liang BioTech Co ROCE % Related Terms

Tien Liang BioTech Co ROCE % Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co ROCE % Chart

Tien Liang BioTech Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

12.42

13.25

4.10

3.27

-0.13

Tien Liang BioTech Co Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															6.05	15.07	-40.22	23.04	1.63

38GF Score

Tien Liang BioTech Co Ltd ROCO:4127

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Tien Liang BioTech Co ROCE % Calculation

Tien Liang BioTech Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-0.621	/	( ( (888.682 - 407.383)	+	(1183.228 - 708.885) )	/ 2 )
	=	-0.621	/	( (481.299	+	474.343)	/ 2 )
	=	-0.621	/	477.821
	=	-0.13 %

Tien Liang BioTech Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	7.752	/	( ( (1223.519 - 745.143)	+	(1183.228 - 708.885) )	/ 2 )
	=	7.752	/	( ( 478.376	+	474.343 )	/ 2 )
	=	7.752	/	476.3595
	=	1.63 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 1.63% mean?

Tien Liang BioTech Co (ROCO:4127) has a ROCE % of 1.63% as of Dec. 2025.

Is Tien Liang BioTech Co's ROCE % too high?

Tien Liang BioTech Co's current ROCE % is 1.63%. The Drug Manufacturers industry median ROCE % is 7.01. Tien Liang BioTech Co's value of 1.63% is 76.7% below this industry median. Overall, Tien Liang BioTech Co has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Tien Liang BioTech Co's ROCE % compare to ZTS and UTHR?

Tien Liang BioTech Co's ROCE % of 1.63% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Tien Liang BioTech Co's value of 1.63% is 76.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tien Liang BioTech Co's current ROCE % of 1.63% is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tien Liang BioTech Co's current ROCE % is 1.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Tien Liang BioTech Co stock overvalued right now?

Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.20, compared to a current price of NT$68.30 — trading 74.2% above its estimated fair value. The current ROCE % is 1.63% and 76.7% below the Drug Manufacturers industry median of 7.01. Tien Liang BioTech Co's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current ROCE % is 1.63% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$68.30 is trading 74.2% above its estimated GF Value™ of NT$39.20. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

ROCE %: 1.63%
GF Value™: NT$39.20 vs. price of NT$68.30 (74.2% above fair value)
GF Score™: 38/100 with 8 warning signs
Industry Position: 76.7% below the Drug Manufacturers median

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tien Liang BioTech Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TPE:1731 ROCO:1780 ROCO:6932 TPE:4108 ROCO:4747 ROCO:1799 ROCO:4120 ROCO:7860 ROCO:8432 ROCO:7829 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN

Website https://www.tlb.com.tw

Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.

38GF Score

Get the complete analysis for ROCO:4127

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$68.30

Price

NT$39.20

GF Value

View ROCO:4127 Analysis

See ROCE % data for all stocks →